Skip to content

Laparoscopic versus Open Total Gastrectomy Combined Distal Pancreaticosplenectomy for T4b Gastric Cancer

Laparoscopic versus Open Total Gastrectomy Combined Distal Pancreaticosplenectomy for T4b Gastric Cancer

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019510
Enrollment
Unknown
Registered
2018-11-15
Start date
2019-01-01
Completion date
Unknown
Last updated
2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

laparoscopic:laparoscopic pancreaticosplenectomy
open:open pancreaticosplenectomy

Sponsors

Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) primary gastric cancer; (2) 18-80 years old; (3) electronic gastroscopy and pathological diagnosis of gastric adenocarcinoma; (4) preoperative CT evaluation of the whole abdomen: clinical T stage T4b, invasion of the pancreas, clinical N stage n0-2, M stage M0 or M1 (resectable), R0 resection is expected; (5) functional status: 0-2 points (ECOG); (6) voluntarily sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) a history of other malignant tumors within 5 years; (2) accompanied by other malignant tumors; (3) have a history of gastric resection; (4) have severe or uncontrolled medical diseases (including liver insufficiency, renal failure, severe diabetes and lung failure, etc.); (5) patients requiring long-term use of hormones or immunosuppressive agents (e.g., steroid or transplant rejection drug therapy); (6) patients with severe or uncontrollable mental diseases; (7) drug abuse and medical, psychological or social conditions may interfere with patients' participation in the study or affect the evaluation of the study results; (8) any unstable situation or situation that may endanger patient safety and compliance; (9) is being treated with anticancer drugs in other clinical trials.

Design outcomes

Primary

MeasureTime frame
3-year overall survival;

Secondary

MeasureTime frame
morbidity;mortality;

Countries

China

Contacts

Public ContactHan Fanghai

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

fh_han@163.com+86 13580317677

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026